5D8J

Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type 2 diabetes.


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3 Å
  • R-Value Free: 0.269 
  • R-Value Work: 0.205 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.

Burak, M.F.Inouye, K.E.White, A.Lee, A.Tuncman, G.Calay, E.S.Sekiya, M.Tirosh, A.Eguchi, K.Birrane, G.Lightwood, D.Howells, L.Odede, G.Hailu, H.West, S.Garlish, R.Neale, H.Doyle, C.Moore, A.Hotamisligil, G.S.

(2015) Sci Transl Med 7: 319ra205-319ra205

  • DOI: 10.1126/scitranslmed.aac6336
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The lipid chaperone aP2/FABP4 has been implicated in the pathology of many immunometabolic diseases, including diabetes in humans, but aP2 has not yet been targeted for therapeutic applications. aP2 is not only an intracellular protein but also an ac ...

    The lipid chaperone aP2/FABP4 has been implicated in the pathology of many immunometabolic diseases, including diabetes in humans, but aP2 has not yet been targeted for therapeutic applications. aP2 is not only an intracellular protein but also an active adipokine that contributes to hyperglycemia by promoting hepatic gluconeogenesis and interfering with peripheral insulin action. Serum aP2 levels are markedly elevated in mouse and human obesity and strongly correlate with metabolic complications. These observations raise the possibility of a new strategy to treat metabolic disease by targeting serum aP2 with a monoclonal antibody (mAb) to aP2. We evaluated mAbs to aP2 and identified one, CA33, that lowered fasting blood glucose, improved systemic glucose metabolism, increased systemic insulin sensitivity, and reduced fat mass and liver steatosis in obese mouse models. We examined the structure of the aP2-CA33 complex and resolved the target epitope by crystallographic studies in comparison to another mAb that lacked efficacy in vivo. In hyperinsulinemic-euglycemic clamp studies, we found that the antidiabetic effect of CA33 was predominantly linked to the regulation of hepatic glucose output and peripheral glucose utilization. The antibody had no effect in aP2-deficient mice, demonstrating its target specificity. We conclude that an aP2 mAb-mediated therapeutic constitutes a feasible approach for the treatment of diabetes.


    Organizational Affiliation

    Department of Genetics and Complex Diseases and Sabri √úlker Center, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Fatty acid-binding protein, adipocyte
A
134Mus musculusMutation(s): 0 
Gene Names: Fabp4 (Ap2)
Find proteins for P04117 (Mus musculus)
Go to UniProtKB:  P04117
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
HA3 Fab Heavy Chain
H
221N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
HA3 Fab Light Chain
L
215N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
A
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3 Å
  • R-Value Free: 0.269 
  • R-Value Work: 0.205 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 71.499α = 90.00
b = 66.040β = 111.67
c = 75.678γ = 90.00
Software Package:
Software NamePurpose
xia2data reduction
REFMACrefinement
PHASERphasing
SCALAdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2015-08-17 
  • Released Date: 2016-01-13 
  • Deposition Author(s): Doyle, C., Birrane, G.

Revision History 

  • Version 1.0: 2016-01-13
    Type: Initial release
  • Version 1.1: 2017-08-02
    Type: Source and taxonomy